Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asfotase Alfa Dose Response in Adult Pediatric-Onset HPP
NCT02797821Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2016
- Primary completion
- Jun 2017
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of asfotase alfa in hypophosphatasia (HPP) (3 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change In Plasma Inorganic Pyrophosphate From Baseline To Pre-3rd Dose At Week 9. Started Jun 2016; status: completed.
02
Drugs
asfotase alfa
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on NCT02797821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02797821.